Valuation Unicycive Therapeutics, Inc.

Stocks

Market Closed - Nasdaq 00:00:00 14/10/2026 +04			5-day change	1st Jan Change
3.730 ^USD	-7.90%		-11.82%	-35.36%

10-01	Unicycive Therapeutics, Inc. Appoints Meredith Manning to its Board of Directors, Each of the Audit, Compensation, and Nominating and Corporate Governance Committees, and Chairperson of the Nominating and Corporate Governance Committee	CI
09-29	Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate	CI

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Market Cap ¹	30.84	8.148	30.16	82.44	124	103.9	-	-
Change	-	-73.58%	270.11%	173.36%	50.43%	-16.21%	-	-
Enterprise Value (EV)	30.84	8.148	30.16	82.44	124	103.9	103.9	103.9
Change	-	-73.58%	270.11%	173.36%	50.43%	-16.21%	0%	0%
P/E	-2.4x	-0.45x	-0.68x	-1.42x	-3.46x	-2.95x	2.03x	0.43x
PBR	-	-	-	-	-	-	-	-
PEG	-	-0x	-0.1x	0x	0x	0.1x	-0x	0x
Capitalization / Revenue	-	8.57x	44.7x	-	-	75.8x	0.69x	0.19x
EV / Revenue	-	0x	0x	-	-	75.8x	0.69x	0.19x
EV / EBITDA	-	-	-	-	-	-	-	-
EV / EBIT	-0x	-0x	-0x	-0x	-0x	-2.73x	1.75x	0.28x
EV / FCF	-0x	-	-0x	-0x	-0x	-3.19x	-5.02x	0.69x
FCF Yield	-18.8%	-	-60.7%	-34.8%	-25.3%	-31.4%	-19.9%	146%
Dividend per Share ²	-	-	-	-	-	-	2.08	5.37
Rate of return	-	-	-	-	-	-	55.8%	144%
EPS ²	-8.6	-12	-12.8	-5.6	-1.67	-1.266	1.834	8.595
Distribution rate	-	-	-	-	-	-	113%	62.5%
Net sales ¹	-	0.951	0.675	-	-	1.37	149.5	546.9
EBITDA	-	-	-	-	-	-	-	-
EBIT ¹	-8.977	-18.05	-20.77	-32.12	-29.52	-38.03	59.54	374.4
Net income ¹	-10.02	-18.06	-31.41	-37.82	-26.56	-35.38	57.12	355
Net Debt	-	-	-	-	-	-	-	-
Reference price ²	20.600	5.400	8.677	7.942	5.770	3.730	3.730	3.730
Nbr of stocks (in thousands)	1,497	1,509	3,475	10,380	21,491	27,855	-	-
Announcement Date	31/03/22	31/03/23	28/03/24	31/03/25	30/03/26	-	-	-

¹USD in Million²USD

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
UNICYCIVE THERAPEUTICS, INC.	-2.95x	-	-	-	104M
WUXI APPTEC CO., LTD.	20.44x	7.28x	14.62x	1.45%	70.44B
ARGENX SE	27.08x	7.4x	23.22x	0.05%	50.31B
LONZA GROUP AG	33.03x	5.94x	17.79x	0.98%	47.51B
IQVIA HOLDINGS INC.	33.58x	3.26x	14.07x	-.--%	42.91B
REVOLUTION MEDICINES, INC.	-19.54x	197.56x	-20.76x	-.--%	40.39B
BEONE MEDICINES AG	46.24x	5.25x	28.83x	-.--%	39.69B
CELLTRION, INC.	26.84x	7.63x	19.74x	0.4%	30.59B
WUXI BIOLOGICS (CAYMAN) INC.	30.94x	6.59x	17.1x	-.--%	26.8B
BIONTECH SE	-13.49x	4.97x	-6x	-.--%	22.36B
Average	18.22x	27.32x	12.07x	0.32%	37.11B
Weighted average by Cap.	22.11x	27.00x	13.15x	0.44%